AbCellera Acquires TetraGenetics to Enhance its Capabilities for Developing Antibodies
Shots:
- AbCellera acquires TetraGenetics in an all-cash transaction that includes up front- milestones based on the achievement of technical milestones related to the development of therapeutics
- The acquisition will combine TetraGenetics’ capabilities with AbCellera’s technology to provides an optimized protein source for AbCellera’s Abs discovery across a range of therapeutic areas. The technology has the potential to unlock the discovery of Abs against validated and drug targets
- TetraGenetics offers a protein expression platform that generates recombinant human ion channels- GPCR- and other transmembrane proteins to support Ab discovery
| Ref: AbCellera | Image: AbCellera
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com